• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

VIVUS, Inc.

NASDAQ:VVUS

$24.59 -$0.18 (-0.73%)

REAL-TIME: Last trade at

3 Health-Care Stocks Crushing the Market

Bio-Pharma Stocks To Watch For Next Week

Friday Options Recap

Orbimed's $3.4B Filing: 2 Stocks It And Other Healthcare Funds Bought In Q1, And Other Trades

Investing in Weight Loss Ahead of This Summer’s FDA Decisions

How to Play an Arena Delay

Here's What Smart Billionaire George Soros Is Buying and Selling

Should Investors Worry About Arena's Offering?

Windstream Corporation and Sirius XM Radio Among Most Active Stocks in Pre-Market Today on the Nasda

Why This Biotech Crushed the Market

A Step Closer to Quadrific Sales

Will the Dow Hold On?

Diet Pill Maker Arena Pharmaceuticals Wins Backing of FDA Advisers

24/7 Wall St. Closing Bell

A Down Day Caps a Brutal Week for the Dow

Let the Obesity-Drug Wars Begin

Whoa! 2 Stocks That Bucked the Dow

The Dow Busts Its Slump

Diet Pill Maker Arena Pharmaceuticals' Stock Jumps Ahead of US Review

Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, AMGN, SVNT)

3 Health-Care Stocks' Monster Moves

Has InterMune Become the Perfect Stock?

Vivus' ED Drug Gets Green Signal - Analyst Blog

Vivus' ED Drug Gets Green Light - Analyst Blog

The 8 Earnings Reports Shaping The Week Ahead (DNDN, EA, RAX, DIS, CSCO, M, NUAN)

Will Novo Nordisk Help You Retire Rich?

This Just In: More Upgrades and Downgrades

Vivus Wins FDA Approval

Another Reason to Get Excited About VIVUS

Fast-Acting Erectile Dysfunction Drug Penetrates The Market

FDA Approves Stendra For Erectile Dysfunction

These Underdogs Are No Dogs

Whoa! Chelsea Therapeutics and Hercules Offshore Rolled Higher

Vivus Awaits Avanafil Approval - Analyst Blog

Arena Shares Sink as Big Dates for Diet Pill Makers Near

Why Did These 2 Stocks Roll Over?

Options Traders Extending Out to September in VIVUS (VVUS)

Company News for April 10, 2012 - Corporate Summary

Wait Continues for Vivus' Qnexa - Analyst Blog

FDA Delay Points to Blockbuster Approval

See More Articles...